20 November 2024

Howe Street Reporter Title

Tag: psilocybin research

  • Today’s Idea: Filament Health’s (FH.NE) psychedelics play

    Today’s Idea: Filament Health’s (FH.NE) psychedelics play

    Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector was experiencing an unprecedented breakout period. Maybe it was because of mainstream media or perhaps it was my nagging parents, but I have always feared psychedelics. Back…

  • Revive Therapeutics (RVV.C) incredible patent-portfolio explained

    Revive Therapeutics (RVV.C) incredible patent-portfolio explained

    Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…

  • Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates

    Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates

    Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according to a press release. The research will be done by Dr. John Fahy with the intention of testing the efficacy of Bucillamine in pre-clinical models of…